Sources
Everything Placebo reads, by domain. None of them endorses or is affiliated with Placebo.
Data
| clinicaltrials.gov | API v2: records, primary outcomes, posted results, status and whyStopped |
| api.fda.gov | openFDA drugsfda: applications and their submissions |
| platform.opentargets.org | GraphQL: target association scores for MONDO_0004975 |
| eutils.ncbi.nlm.nih.gov | PubMed counts and abstracts |
| rpc.mainnet.chain.robinhood.com | Robinhood Chain: the contract's events and state |
| robinhoodchain.blockscout.com | the explorer every transaction links to |
Papers
- Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Research & Therapy 2014;6(4):37. PMID 25024750.
- Cummings JL, Zhou Y, Yang Y, Zhong K, Fonseca J, Osse AL, Cheng F. Alzheimer's disease drug development pipeline: 2026. Alzheimer's & Dementia: TRCI 2026;12(2):e70251. PMID 42095064. "There are currently 158 drugs in 192 AD trials."
Context
primamente.com/challenges: the Alzheimer's Translation Challenge, with the Alzheimer's Disease Data Initiative. Placebo opens one market on it and uses none of its data. agentalois.com generates and tests hypotheses in public; Placebo prices other people's experiments and never proposes one.